A Phase 4, Double-blind, Sequential Cohort Study of Pain Treatment and Recovery After Total Knee Arthroplasty

Vertex Pharmaceuticals Incorporated

Summary

The purpose of the study is to characterize opioid use after total knee arthroplasty (TKA).

Eligibility

Age range: 18–80 years
Sex: All
Healthy volunteers: No

Detailed criteria

Key Inclusion Criteria: * Body mass index (BMI) of greater than or equal to (≥) 18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg/m\^2) * Scheduled to undergo an elective primary unilateral TKA surgery Key Exclusion Criteria: \- History of previous TKA surgery on incident side Other protocol defined Inclusion/Exclusion criteria will apply.

Interventions

Drug
Suzetrigine
Tablets for oral administration.
Drug
Placebo
Placebo matched to SUZ for oral administration

Locations (2)

Legent Orthopedic and Spine Hospital
Bellaire, Texas
Memorial Hermann Village Office
Houston, Texas

Summary

Eligibility

Interventions

Locations (2)

Conditions